Exane Derivatives’s Blueprint Medicines BPMC Stock Holding History

Exane Derivatives’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$404	Sell	8 -559	-99%	-$32.7K	﹤0.01%	596
2022 Q1	$36.2K	Buy	567 +178	+46%	+$12.8K	0.01%	604
2021 Q4	$41.7K	Buy	389 +362	+1,341%	+$37.9K	0.01%	513
2021 Q3	$2.78K	Hold	27	–	–	﹤0.01%	780
2021 Q2	$2.23K	Hold	27	–	–	﹤0.01%	811
2021 Q1	$2.63K	Hold	27	–	–	﹤0.01%	662
2020 Q4	$3.03K	Hold	27	–	–	﹤0.01%	592
2020 Q3	$2.5K	Hold	27	–	–	﹤0.01%	547
2020 Q2	$2.11K	Sell	27 -1,743	-98%	-$118K	﹤0.01%	501
2020 Q1	$104K	Buy	1,770 +1,765	+35,300%	+$114K	0.03%	278
2019 Q4	$401	Hold	5	–	–	﹤0.01%	629
2019 Q3	$367	Hold	5	–	–	﹤0.01%	604
2019 Q2	$471	Sell	5 -90	-95%	-$7.43K	﹤0.01%	601
2019 Q1	$7.6K	Buy	95 +82	+631%	+$6.06K	﹤0.01%	406
2018 Q4	$701	Hold	13	–	–	﹤0.01%	588
2018 Q3	$1.02K	Sell	13 -1,449	-99%	-$101K	﹤0.01%	537
2018 Q2	$90.7K	Hold	1,462	–	–	0.02%	346
2018 Q1	$127K	Buy	+1,462	New	+$126K	0.03%	274

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Exane Derivatives's BPMC Position: Q2 2022 in Review

Exane Derivatives reduced its Blueprint Medicines (BPMC) stake by 99% in Q2 2022, selling an estimated $32.7K and leaving 8 shares worth $404. The position accounts for ﹤0.01% of the portfolio, ranked #596.

Exane Derivatives first reported a position in BPMC in Q1 2018 and has held it in 18 quarters since. The position peaked at $127K in Q1 2018. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

Exane Derivatives held 8 shares of Blueprint Medicines worth $404 as of Q2 2022.
Exane Derivatives sold 559 Blueprint Medicines shares in Q2 2022, an estimated $32.7K.
Blueprint Medicines made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #596 holding.
Exane Derivatives first reported a position in Blueprint Medicines in Q1 2018 and has held it in 18 quarters since.
Exane Derivatives's Blueprint Medicines position peaked at $127K in Q1 2018.
237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.